Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) | PA 21 180

Opportunity Information: Apply for PA 21 180

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) is a National Institutes of Health (NIH) grant opportunity (Funding Opportunity Number PA-21-180) designed to support early-stage, pilot, and preliminary studies that lay the groundwork for larger, full-scale health services research effectiveness trials. The central aim is to help investigators test and refine real-world approaches to improving how substance use disorder (SUD) care is delivered, financed, accessed, and experienced, with a strong emphasis on generating the kind of practical evidence needed before launching more expensive and complex multi-site trials.

The projects this announcement is trying to stimulate focus on health services and economic research related to treatments and services for drug, alcohol, and tobacco use disorders. That includes work that examines how to optimize access to care, improve quality and clinical effectiveness, increase affordability, and ensure appropriate utilization of evidence-based (and potentially evidence-generating) services. A key point is that NIH is not limiting applicants to only brand-new innovations; the FOA also explicitly welcomes studies of common, widely used practices and policies that are already happening in routine care but still lack a solid evidence base. In other words, the opportunity is meant to strengthen decision-making for systems, providers, and policymakers by supporting projects that clarify what works, for whom, in what settings, and at what cost.

Because it uses the R34 mechanism, the emphasis is on preparatory and feasibility-oriented research rather than definitive, fully powered effectiveness trials. Applicants are encouraged to use these funds to assess whether a proposed approach is feasible in the intended setting, acceptable to patients, providers, or organizations, and useful enough to justify scaling up. This can include the kinds of foundational tasks that make later trials viable, such as refining protocols, testing recruitment and retention strategies, verifying data collection methods, examining implementation barriers, piloting outcome measures, and establishing partnerships with clinical sites, community organizations, health systems, or payers. The FOA also highlights the value of understanding practical considerations like workflow fit, staffing needs, and resource constraints, which often determine whether an intervention or policy can be sustained outside of a research context.

The scope of potential studies is broad. Trials and evaluations under this FOA may examine interventions (for example, new care models, care coordination strategies, digital supports, contingency management workflows, medication treatment delivery improvements, or smoking cessation service integrations), practices (such as screening and referral processes, stepped care, telehealth delivery strategies, or workforce training approaches), and policies (including payment models, coverage rules, service authorization requirements, or organizational policies that affect treatment entry and continuity). Importantly, the FOA also recognizes that many people with substance use disorders have comorbid medical and mental health conditions, so studies that address or integrate services for these co-occurring conditions are explicitly within bounds.

This opportunity is categorized as discretionary funding and uses the grant funding instrument. It falls under the Education and Health funding activity category and is associated with CFDA numbers 93.273 and 93.279. The announcement lists an original closing date of 2025-01-07, and it was created on 2021-05-11. While the provided source data does not specify an award ceiling or expected number of awards, the intent of the R34 mechanism generally aligns with supporting smaller, time-limited projects that produce actionable pilot data and a credible plan for subsequent, larger-scale submission.

Eligibility is intentionally wide to encourage participation from many kinds of organizations involved in health and social service delivery. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized tribal governments); public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and other entities. The FOA also calls out additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and even non-U.S. entities (foreign organizations). This wide eligibility signals NIH interest in research that reflects diverse systems of care and community contexts, including underserved and high-need populations.

Finally, the "(Clinical Trial Optional)" designation means applicants may propose a study that includes a clinical trial component if it fits the aims, but they are not required to run a clinical trial to be responsive. In practical terms, that allows applications ranging from pilot randomized or pragmatic trials to other rigorous preliminary study designs focused on services research questions, including economic components such as cost, cost-effectiveness, or budget impact analyses, when relevant. Overall, the FOA is best understood as a launchpad: it funds the early, high-value work needed to demonstrate readiness for a larger effectiveness trial and to reduce uncertainty about whether an approach to SUD treatment and related services can realistically be implemented and evaluated at scale.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273, 93.279.
• This funding opportunity was created on 2021-05-11.
• Applicants must submit their applications by 2025-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 21 180

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: